23012-16-0

Basic information

• Product Name: 2-Phenyl-1,3-oxazole-4-carboxylic acid
• Synonyms: 2-phenyloxazole-4-carboxylic acid;4-Carboxy-2-phenyl-1,3-oxazole;4-Oxazolecarboxylicacid, 2-phenyl-;2-Phenyl-1,3-oxazole-4-carboxylic acid
• CAS NO: 23012-16-0
• Molecular Formula: C₁₀H₇NO₃
• Molecular Weight: 189.17
• Product Categories: Oxazoles, Isoxazoles & Benzoxazoles;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Carboxylic Acids
• Mol File: 23012-16-0.mol

Chemical Properties

• Boiling Point: 396.4 °C at 760 mmHg
• Flash Point: 193.5 °C
• Appearance: /
• Density: 1.32 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Phenyl-1,3-oxazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-1,3-oxazole-4-carboxylic acid(23012-16-0)
• EPA Substance Registry System: 2-Phenyl-1,3-oxazole-4-carboxylic acid(23012-16-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 23012-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
2-Phenyl-1,3-oxazole-4-carboxylic acid serves as a promising agent for anti-inflammatory and antibacterial purposes. Its ability to modulate biological processes and target specific pathways makes it a candidate for the development of new drugs to combat inflammation and bacterial infections.
Used in Organic Synthesis:
In the realm of organic synthesis, 2-Phenyl-1,3-oxazole-4-carboxylic acid is utilized as a key building block for the preparation of a variety of bioactive molecules. Its unique structure allows for the creation of diverse chemical entities with potential applications in medicine and other industries.
Used in Medicinal Chemistry Research:
2-Phenyl-1,3-oxazole-4-carboxylic acid is an important compound in medicinal chemistry, where it is studied for its potential to contribute to the discovery of new therapeutic agents. Its structural attributes and functional groups make it a versatile component in the design and synthesis of novel pharmaceuticals.
Used in Chemical Research:
2-Phenyl-1,3-oxazole-4-carboxylic acid also holds significance in broader chemical research, where its properties and reactivity are explored to understand its behavior in various chemical reactions. This knowledge can be applied to optimize synthetic routes and develop new methodologies in organic chemistry.

Upstream product

• 39819-39-1 2-phenyl-oxazole-4-carboxylic acid ethyl ester 
• 91349-15-4 2-benzoylamino-3-chloro-acrylic acid methyl ester 
• 1113-59-3 bromopyruvic acid 
• 55-21-0 benzamide 
• 59171-72-1 2-phenyl-oxazole-4-carboxylic acid methyl ester 
• 20989-42-8 N-benzoylserine methyl ester 
• 55044-06-9 methyl 2-phenyl-2-oxazoline-4-carboxylate 
• 37592-54-4 isopropyl 2-phenyl-4,5-dihydro-1,3-oxazole-4-carboxylate 
• 98-88-4 benzoyl chloride 
• 138739-05-6 2-benzoylamino-3-hydroxypropionic acid benzyl ester 
• 609366-75-8 (S)-benzyl 2-phenyl-4,5-dihydrooxazole-4-carboxylate 
• 100-52-7 benzaldehyde 
• 138478-13-4 isopropyl N-benzoylaziridine-2-carboxylate 

Downstream Products

• 59171-72-1 2-phenyl-oxazole-4-carboxylic acid methyl ester 
• 670-96-2 2-Phenylimidazole 
• 20662-88-8 2-phenyloxazole 
• 92868-15-0 2-phenyl-oxazole-4-carboxylic acid anilide 
• 587884-72-8 2-phenyl-oxazole-4-carboxylic acid (2-iodo-phenyl)-amide 
• 59398-98-0 (2-phenyl-1,3-oxazol-4-yl)methanol 
• 97492-81-4 2-phenyl-oxazole-4-carbothioic acid anilide 
• 1204-70-2 2-phenyl-1,3-oxazole-4-carbonyl chloride 
• 1334686-89-3 2-phenyl-N,N-di-n-propyl-1,3-oxazole-4-carboxamide 
• 1334686-90-6 N,N-di-n-butyl-2-phenyl-1,3-oxazole-4-carboxamide 
• 1334686-91-7 N,N-di-n-pentyl-2-phenyl-1,3-oxazole-4-carboxamide 
• 1334686-92-8 N,N-di-n-hexyl-2-phenyl-1,3-oxazole-4-carboxamide 
• 1334686-93-9 N-benzyl-N-ethyl-2-phenyl-1,3-oxazole-4-carboxamide 
• 1334686-94-0 N-butyl-N-methyl-2-phenyl-1,3-oxazole-4-carboxamide 

Relevant articles and documents

Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors

In this present study, a series of 5-phenyl-2-furan and 4-phenyl-2-oxazole derivatives were designed and synthesized as phosphodiesterase type 4 (PDE4) inhibitors. In vitro results showed that the synthesized compounds exhibited considerable inhibitory ac

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

Towards New Tricyclic Motifs: Intramolecular C–H Arylation as the Key Step in a Formal [3+3] Cyclocondensation Strategy

Tricyclic scaffolds structurally related to the well-known benzodiazepine class of drugs show diverse biological activities strikingly different from those of their benzodiazepine counterparts. Interested by this scaffold-hopping perspective, we previousl

Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents

To further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (1), a series of aromatic heterocyclic derivatives were designed, synthesized and evaluated for in vitro antifungal activity. Many of the target compounds showed good inhibitory activity against Candida albicans and Cryptococcus neoformans. In particular, the isoxazole nuclei were more suited for improving the activity against Aspergillus spp. Among these compounds, 2-F substituted analogues 23g and 23h displayed the most remarkable in vitro activity against Candida spp., C. neoformans, A. fumigatus and fluconazole-resistant C.alb. strains, which is superior or comparable to the activity of the reference drugs fluconazole and voriconazole. Notably, the compounds 23g and 23h exhibited low inhibition profiles for various isoforms of human cytochrome P450 and excellent blood plasma stability.

Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors

In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed and synthesized in a concise way, some of which exhibited considerable inhibitory activity against PDE4B and blockade of LPS-induced TNF-α release. Compound

Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors

Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins. Here we report the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids by a short synthetic proce

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

CXCR7 ANTAGONISTS

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds

Tuberculosis (TB) is a devastating disease resulting in a death every 20 s. Thus, new drugs are urgently needed. Herein we report ten classes of compounds - oxazoline, oxazole, thiazoline, thiazole, pyrazole, pyridine, isoxazole, imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine and imidazo[1,2-c]pyrimidine - which have good (micromolar) to excellent (sub-micromolar) antitubercular potency. The 5,6-fused heteroaromatic compounds were the most potent with MIC's as low as 37Rv, clinically relevant drug sensitive, multi- and extensively resistant Mtb strains as well as having good in vitro metabolic stability.

Hydroxamic Acids as Potent Inhibitors of FeII and MnII E. coli Methionine Aminopeptidase: Biological Activities and X-ray Structures of Oxazole Hydroxamate-EcMetAP-Mn Complexes

New series of acids and hydroxamic acids linked to five-membered heterocycles including furan, oxazole, 1,2,4- or 1,3,4-oxadiazole, and imidazole were synthesized and tested as inhibitors against the FeII, CoII, and MnII f